ClinicalTrials.gg

Program

recombinant FVIIa

Also written as “activated recombinant human factor VII”, “eptacog alfa (activated)” and “Coagulation Factor VIIa (Recombinant)”.

Its studies are mostly in Hemophilia A · Cerebral Hemorrhage · Wounds and Injuries · Fibrosis · Postpartum Hemorrhage, led by 4 companies.

Furthest: phase 4, since Dec 11, 200741 company-led studies, 1 open or runningNext primary completion: Aug 26, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk361 open or runningphase 4since Dec 11, 2007Jan 19, 2005Aug 26, 2027phase 4 · NCT07157423
Laboratoire français de Fractionnement et de Biotechnologies20 open or runningphase 3since Sep 9, 2015Sep 9, 2015none ahead
rEVO Biologics20 open or runningphase 3since Dec 18, 2013Oct 15, 2012none ahead
AryoGen Pharmed10 open or runningphase 3since Mar 4, 2017Mar 4, 2017none ahead

Also a collaborator on its studies: LFB USA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Jan 19, 2005.

  1. Jul 8, 2011Phase 3 study in Congenital Bleeding DisorderNovo Nordisk · NCT01392547 · 72 enrolled · United States, Austria, Brazil and more
  2. Mar 21, 20127 phase 1 studiesNovo Nordisk · NCT01562457, NCT01561950, NCT01561937 and 4 more
  3. Mar 21, 2012Phase 4 study in Congenital Bleeding DisorderNovo Nordisk · NCT01561391 · 36 enrolled · United States
  4. Mar 21, 20128 phase 2 studiesNovo Nordisk · NCT01561352, NCT01563458, NCT01562821 and 5 more
  5. Mar 22, 2012Phase 3 study in Acquired Bleeding DisorderNovo Nordisk · NCT01562574 · 82 enrolled · Australia
  6. May 14, 20122 phase 2 studiesNovo Nordisk · NCT01601613, NCT01601457
  7. Oct 15, 2012rEVO Biologics’ first study: phase 1 study in Hemophilia ANew to rEVO BiologicsrEVO Biologics · NCT01708564 · 15 enrolled · United States, Netherlands
  8. Sep 13, 2013Phase 1 study in Hemophilia ANovo Nordisk · NCT01949792 · 6 enrolled · Spain
  9. Dec 18, 2013Phase 3 study in Hemophilia A With InhibitorsrEVO Biologics · NCT02020369 · 27 enrolled · United States, Belarus, Bulgaria and more
  10. Jan 28, 2014Phase 1 study in Hemophilia ANovo Nordisk · NCT02084810
  11. Sep 9, 2015Laboratoire français de Fractionnement et de Biotechnologies’ first study: phase 3 study in Hemophilia ANew to Laboratoire français de Fractionnement et de BiotechnologiesLaboratoire français de Fractionnement et de Biotechnologies · NCT02548143 · 12 enrolled · United States, Mexico, Russian Federation and more
  12. Mar 4, 2017AryoGen Pharmed’s first study: phase 3 study in Factor VII DeficiencyNew to AryoGen PharmedAryoGen Pharmed · NCT03079063 · 24 enrolled · Iran, Islamic Republic of
  13. Dec 21, 2022Phase 3 study in Hemophilia ALaboratoire français de Fractionnement et de Biotechnologies · NCT05695391 · 2 enrolled · United States, Malaysia, Mexico and more
  14. Aug 19, 2025Phase 4 study in Postpartum HemorrhageNovo Nordisk · NCT07157423 · 64 planned · India

Ahead

  1. Aug 26, 2027Primary completion: phase 4 study in Postpartum HemorrhageNovo Nordisk · NCT07157423

TargetBeta

F7 →read by rule
“A recombinant form of the vitamin K-dependent glycoprotein and coagulation factor VIIa (FVIIa), that can be used for the treatment of bleeding episodes and perioperative management in patients with hemophilia, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia”NCIt, by rule

Studies

All 41 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07157423Postpartum Hemorrhage · India4RecruitingNovo NordiskAug 26, 202764
NCT05695391Hemophilia A · United States, Malaysia, Mexico and more3TerminatedLaboratoire français de Fractionnement et de BiotechnologiesMay 28, 20252
NCT03079063Factor VII Deficiency · Iran, Islamic Republic of3CompletedAryoGen PharmedNov 30, 202024
NCT02548143Hemophilia A · United States, Mexico, Russian Federation and more3CompletedLaboratoire français de Fractionnement et de BiotechnologiesAug 6, 201712
NCT02084810Hemophilia A1WithdrawnNovo NordiskJul 20140
NCT02020369Hemophilia A With Inhibitors · United States, Belarus, Bulgaria and more3CompletedrEVO BiologicsJul 201527
NCT01949792Hemophilia A · Spain1CompletedNovo NordiskNov 20136
NCT01708564Hemophilia A · United States, Netherlands1CompletedrEVO BiologicsJun 201315
NCT01601457Wounds and Injuries · United Kingdom2CompletedNovo NordiskApr 200448
NCT01601613Dengue · Malaysia, Philippines, Thailand2CompletedNovo NordiskNov 200228
NCT01566786Cerebral Hemorrhage · Australia, Denmark, Finland and more2CompletedNovo NordiskOct 200248
NCT01564563Acquired Bleeding Disorder · United States2TerminatedNovo NordiskOct 27, 200311
NCT01563523Wounds and Injuries · Australia, Austria, Canada and more2CompletedNovo NordiskOct 2003283
NCT01563471Congenital Bleeding Disorder · France1CompletedNovo NordiskJul 200239
NCT01563445Cerebral Hemorrhage · United States2CompletedNovo NordiskMar 200340
NCT01563458Acquired Bleeding Disorder · Australia, Canada, France and more2CompletedNovo NordiskAug 2003208
NCT01562821Fibrosis · China, Taiwan, Thailand2CompletedNovo NordiskDec 2002235
NCT01562587Hemophilia A · Germany, Greece, Italy and more1CompletedNovo NordiskMay 200318
NCT01562574Acquired Bleeding Disorder · Australia3CompletedNovo NordiskAug 200482
NCT01562158Acquired Bleeding Disorder · United States, Australia, Austria and more2CompletedNovo NordiskOct 2003100
NCT01562457Hemophilia A · France, Germany, Israel1CompletedNovo NordiskApr 200630
NCT01561950Haemostasis · United States1TerminatedNovo NordiskJan 200991
NCT01561937Haemostasis · United States1CompletedNovo NordiskJul 2008127
NCT01561924Congenital Bleeding Disorder · United States, Denmark, France and more1CompletedNovo NordiskMay 200617
NCT01561417Thrombasthenia · France1CompletedNovo NordiskSep 200628
NCT01561391Congenital Bleeding Disorder · United States4CompletedNovo NordiskMay 200436
NCT01561352Cystitis, Hemorrhagic · United States2CompletedNovo NordiskNov 20037
NCT01392547Congenital Bleeding Disorder · United States, Austria, Brazil and more3CompletedNovo NordiskAug 201272
NCT00571584Congenital Bleeding Disorder · France, Hungary, Israel and more4CompletedNovo NordiskMar 200424
NCT00486278Hemophilia A · United States, Argentina, Brazil and more2CompletedNovo NordiskJun 201051
NCT00426803Cerebral Hemorrhage · Australia, Austria, Belgium and more2CompletedNovo NordiskJun 2004400
NCT00323570Wounds and Injuries · United States3WithdrawnNovo NordiskJun 20070
NCT00266006Cerebral Hemorrhage · Japan2CompletedNovo NordiskApr 200790
NCT00184548Wounds and Injuries · United States, Brazil, Czech Republic and more3TerminatedNovo NordiskSep 2008554
NCT00154492Fibrosis · Austria, Czech Republic, Denmark and more2CompletedNovo NordiskAug 2006265
NCT00154427Acquired Bleeding Disorder · United States, Argentina, Brazil and more2TerminatedNovo NordiskNov 2007172
NCT00127283Cerebral Hemorrhage · United States, Australia, Austria and more3CompletedNovo NordiskJan 2007829
NCT00123591Wounds and Injuries · Canada, Finland, Germany and more2CompletedNovo NordiskMay 200696
NCT00108758Congenital Bleeding Disorder · United States, Argentina, Brazil and more2CompletedNovo NordiskNov 200523
NCT00104455Congenital Bleeding Disorder · United States1CompletedNovo NordiskNov 200464
NCT00102037Acquired Bleeding Disorder · United States2CompletedNovo NordiskFeb 200650

How it is read

Names in the registry

  • “activated recombinant human factor VII”, 32 entries
  • “eptacog alfa (activated)”, 12 entries
  • “Coagulation Factor VIIa (Recombinant)”, 3 entries
  • “Eptacog alfa (NovoSeven)”, 1 entry
  • “Eptacog alfa, biosimilar”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.